MIRA Stock Catalyst: MIRA Pharmaceuticals Announces Reversal of PTSD-Like Symptoms in Animal Study

Sep 15, 2025 · 4:03pm ET

Supports ongoing clinical development of Ketamir-2.

Max move

+47.9%

High of day $2.07

Sparker timei

4:03pm ET

MIRA · Sep 15, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

MIRA Pharmaceuticals, Inc. (XNAS: MIRA) announced that its drug candidate, Ketamir-2, successfully reversed PTSD-like symptoms in an animal study. This development supports the ongoing clinical development of the drug.

The company did not provide specific figures or comparisons in this announcement. The study results are a significant step forward for MIRA Pharmaceuticals as it continues to advance Ketamir-2 through clinical trials.

As of the latest available data, MIRA Pharmaceuticals has a free float of 34,944,300 shares and 41,876,100 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time MIRA sparks.

Download Sniper App →

Catch the next MIRA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →